References
Crayton H, Heyman RA, Rosmann HS. A multimodal approach to managing the symptoms of multiple sclerosis. Neurology 2004; 63: S12–8
Tomson T, Tybring G, Bertilsson L, et al. Carbamazepine therapy in trigeminal neuralgia: clinical effects in relation to plasma concentration. Arch Neurol 1980; 37: 699–703
Tomson T, Bertilsson L. Potent therapeutic effect of carbamazepine-10,11-epoxide in trigeminal neuralgia. Arch Neurol 1984; 41: 588–601
Cheshire WP. Trigeminal neuralgia: a guide to drug choice. CNS Drugs 1997; 7: 98–110
Sindrup SH, Jensen TS. Pharmacotherapy of trigeminal neuralgia. Clin J Pain 2002; 18: 22–7
Peiris JB, Perera GLS, Devendra SV, et al. Sodium valproate in trigeminal neuralgia [letter]. Med J Aust 1980; 2: 278
Desai N, Shah K, Gandhi I. Baclofen sodium valproate combination in carbamazepine resistant trigeminal neuralgia: a double blind clinical trial. Cephalalgia 1991; 11Suppl. 11: 321–2
Zakrzewska JM, Chaudhry Z, Nurmikko TJ, et al. Lamotrigine (Lamictal) in refractory trigeminal neuralgia: results from a double-blind placebo controlled crossover trial. Pain 1997; 73: 223–30
Khan OA. Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients. Neurology 1998; 51: 611–4
Zvartau-Hind M, Din MU, Gilani A, et al. Topiramate relieves refractory trigeminal neuralgia in MS patients. Neurology 2000; 55: 1587–8
Spina E, Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord 2004; 6: 57–65
Jensen MP, Turner JA, Romano JM. What is the maximum number of levels needed in pain intensity measurement? Pain 1994; 58: 387–92
Berthier F, Potel G, Leconte P, et al. Comparative study of methods of measuring acute pain intensity in an ED. Am J Emerg Med 1998; 16: 132–6
Perucca E. An introduction to antiepileptic drugs. Epilepsia 2005; 46: 31–7
Gilron I, Booher SL, Rowan JS, et al. Topiramate in trigeminal neuralgia: a randomized, placebo-controlled multiple crossover pilot study. Clin Neuropharmacol 2001; 24(2): 109–12
Burchiel KJ. Abnormal impulse generation in focally demyelinated trigeminal roots. J Neurosurg 1980; 53: 674–83
Sakurai M, Kanazawa I. Positive symptoms in multiple sclerosis: their treatment with sodium channel blockers, lidocaine and mexiletine. J Neurol Sci 1999; 15: 162–8
Solaro C, Lunardi GL, Capello E, et al. An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. Neurology 1998; 51: 609–11
Russo E, Constanti A, Ferreri G, et al. Nifedipine affects the anticonvulsant activity of topiramate in various animal models of epilepsy. Neuropharmacology 2004; 46: 865–78
Tidwell A, Swims M. Review of the newer antiepileptic drugs. Am J Manag Care 2003; 9: 253–76
Nieto-Barrera M. Characteristics and indications of topiramate. Rev Neurol 2002; 35Suppl. 1: S88–95
Bialer M, Doose DR, Murthy B, et al. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet 2004; 43: 763–80
Acknowledgements
The authors acknowledge financial support for this study from the Ministero della Salute (Programma di Ricerca Finalizzata anno 2002; Farmaci e fitoterapici, impatto sulla salute, vigilanza e sviluppo di un modello organizzativo interregionale. Programmi Speciali ex Art. 12, D.Lgs 502/99). The authors have no conflicts of interest that are directly relevant to the contents of this case report.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Siniscalchi, A., Gallelli, L., Scornaienghi, D. et al. Topiramate Therapy for Symptomatic Trigeminal Neuralgia. Clin. Drug Investig. 26, 113–115 (2006). https://doi.org/10.2165/00044011-200626020-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00044011-200626020-00006